Guidance Capital Inc. Invests $380,000 in Progyny, Inc. (NASDAQ:PGNY)

Guidance Capital Inc. bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 22,001 shares of the company’s stock, valued at approximately $380,000.

Several other large investors have also made changes to their positions in PGNY. Creative Planning raised its stake in shares of Progyny by 13.8% during the 2nd quarter. Creative Planning now owns 10,564 shares of the company’s stock worth $302,000 after buying an additional 1,283 shares during the period. SG Americas Securities LLC increased its position in shares of Progyny by 299.2% during the third quarter. SG Americas Securities LLC now owns 52,152 shares of the company’s stock worth $874,000 after purchasing an additional 39,089 shares in the last quarter. Leibman Financial Services Inc. increased its position in shares of Progyny by 27.4% during the third quarter. Leibman Financial Services Inc. now owns 31,637 shares of the company’s stock worth $530,000 after purchasing an additional 6,805 shares in the last quarter. Mendota Financial Group LLC purchased a new stake in shares of Progyny during the third quarter worth approximately $56,000. Finally, Everence Capital Management Inc. purchased a new stake in shares of Progyny during the third quarter worth approximately $173,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Chairman David J. Schlanger bought 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the purchase, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Anevski bought 209,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company’s stock.

Progyny Stock Down 3.1 %

Shares of Progyny stock opened at $22.72 on Thursday. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08. The business’s fifty day simple moving average is $18.08 and its 200-day simple moving average is $19.05. The firm has a market cap of $1.93 billion, a PE ratio of 39.17, a price-to-earnings-growth ratio of 2.32 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. During the same period last year, the company earned $0.16 EPS. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. As a group, equities analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on PGNY shares. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group dropped their price target on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Bank of America dropped their price target on Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Truist Financial reiterated a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Barclays dropped their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $25.50.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.